Tag: 212Pb

10Jan 2018 by Ronny Allan 10 Comments

PRRT – The Sequel? – Clinical trial of Targeted Alpha-emitter Therapy (TAT) – 212 Pb-AR-RMX

PRRT – The Sequel? – Clinical trial of Targeted Alpha-emitter Therapy (TAT) – 212 Pb-AR-RMX

Living with Neuroendocrine Cancer, Technical NETs

[caption id="attachment_12014" align="aligncenter" width="500"] Radioimmunotherapy[/caption] In 2018, RadioMedix Inc. and Areva (parent company Orano Med) initiated the Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor (SSTR) positive Neuroendocrine Tumors (NETs) - an NIH supported trial. AlphaMedixTM is composed of a somatostatin analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT). This open-label, dose escalation study’s objective is to determine safety, bio-distribution, and preliminary effectiveness of 212 Pb-AR-RMX in adult patients with differentiated (sic) NETs. "Targeted Alpha-emitter Therapy (TAT) is the wave of the future in nuclear oncology and has a tremendous potential to treat patients with NET and overcome some of the limitations of current Peptide Receptor Radionuclide Therapy (PRRT)” said Dr. Ebrahim S. Delpassand, Chairman and CEO of RadioMedix, sponsor of the trial. They further announced on 21…

The case of Justice Ruth Bader Ginsburg vs Cancer

The news that Justice Ruth Bader Ginsburg (RBG) has been treated for ‘Pancreatic Cancer’ has hit the headlines and effectively gone viral. She is not only famous for being a member of the US Supreme Court, but also because she has had many bouts with cancer in the past. What has also gone viral, but […]

Clinical Trials – Surufatinib for Neuroendocrine Cancer

I first heard about this drug at ENETS Barcelona 2017 and then again in 2018. It’s now starting to be discussed in USA including at the 2019 ASCO conference. It was known then as Sulfatinib but for reasons unclear to me it was changed later to Surufatinib. It’s a novel, oral angio-immuno kinase inhibitor that selectively […]

Cancer kills but so can fake cures

No matter where you look on social media, there are millions of sites claiming that ‘this’ and ‘that’ can cure cancer. If you analyse some of the things that can apparently ‘cure’ cancer, you will normally find that behind these fantasies, there is someone selling something, a book, a video, a product. I was also […]

Pancreatic Neuroendocrine Tumours – surgical decisions and new research on molecular sub-types

I offer you two subjects in one article but they are overlapping and very related. The piece of research in the 2nd half of the article is very exciting – did you know researchers have found there are two main sub-types of pNETs, one less likely to recur and metastasise than the other? This will […]

Ronny Allan – Living with Neuroendocrine Neoplasms – Thanks a MILLION

I’m totally astonished to have been able to accumulate a million views of my blog around the middle of June 2019. When I first set it up in Apr 2014, it was just to help spread awareness whilst I was walking the 84 miles of Hadrian’s Wall with my wife Chris. I never thought for one […]

Phase 1 clinical trial of single agent PV-10 for the treatment of symptomatic neuroendocrine tumors (NET) metastatic to the liver

An interesting trial from Provectus Biopharmaceuticals Inc. Phase 1 results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL from May 31-June 4, 2019 In an ogoing Phase 1 clinical trial of single agent PV-10 for the treatment of symptomatic neuroendocrine tumors (NET) metastatic to the liver. […]